Novel approaches to oral immunization for hepatitis B

Current Infectious Disease Reports

Volumn 13, Issue 1, 2011, Pages 4-12

  Tiwari, Shailja ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Adjuvant; Alum; Bilisomes; Cell mediated immunity; Chitosan; Cholera toxin B; Hepatitis B; Hepatitis B surface antigen (HBsAg); Humoral immunity; Lectin; Liposomes; M cells; Mucous associated lymphoid tissue (MALT); Niosomes; Novel drug delivery system; Oral immune induction; Particulate carrier; Peyer's patches; Poly(lactic co glycolic acids) (PLGA); Secretory immunoglobulin A (sIgA)

Indexed keywords

ADENOVIRUS VECTOR; ALEURIA AURANTIA LECTIN; ALGINIC ACID; ARGINYLGLYCYLASPARTIC ACID; BIOLOSOME; CHITOSAN; CHOLERA TOXIN B SUBUNIT; DRUG CARRIER; GAMMA INTERFERON; GELATIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; LEVAMISOLE; LIPOSOME; NAKED DNA; NIOSOME; PLANT LECTIN; POLYACRYLIC ACID; POLYGLACTIN; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME; WHEAT GERM AGGLUTININ;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; EFFECTOR CELL; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE ACTIVATION; TOBACCO; TRANSGENIC PLANT;

EID: 79551511735     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0152-x     Document Type: Article

References (47)

1. MR Hilleman 2003 Critical overview and outlook: pathogenesis, prevention and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus Vaccine 21 4626 4649 1:CAS:528:DC%2BD3sXosVKktbw%3D 10.1016/S0264-410X(03)00529- 2 14585670 (Pubitemid 37329857)
2. FV Chisari C Ferrari 1995 Hepatitis B virus immunopathogenesis Annu Rev Immunol 13 29 60 1:CAS:528:DyaK2MXltFamtLY%3D 10.1146/annurev.iy.13.040195. 000333 7612225
3. RK Gupta 1998 Aluminum compounds as vaccine adjuvants Adv Drug Deliv Rev 32 3 155 172 1:CAS:528:DyaK1cXivVCmtrY%3D 10.1016/S0169-409X(98)00008-8 10837642 (Pubitemid 28267407)
4. PL Ogra H Faden RC Welliver 2001 Vaccination strategies for mucosal immune responses Clin Microbiol Rev 14 2 430 445 1:CAS:528:DC%2BD3MXjtlKht7w%3D 10.1128/CMR.14.2.430-445.2001 11292646 (Pubitemid 32294678)
5. J Nugent AL Po EM Scott 1998 Design and delivery of non-parenteral vaccines J Clin Pharm Ther 23 4 257 285 1:CAS:528:DyaK1MXhsVyjsw%3D%3D 9867311
6. E Nilsen K Lundin R Krajd, et al. 1995 Giuten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytoldnes with Th1 orThO profile dominated by interferon -γ Gut 37 766 776 1:CAS:528:DyaK28XmvFChsw%3D%3D 10.1136/gut.37.6.766 8537046
7. A Gebert HJ Rothkötter R Pabst 1996 M cells in Peyer's patches of the intestine Int Rev Cytol 167 91 159 1:CAS:528:DyaK28XlvFejtrk%3D 10.1016/S0074-7696(08)61346-7 8768493
8. M Rescigno M Urbano B Valzasina, et al. 2001 Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria Nat Immunol 2 361 367 1:CAS:528:DC%2BD3MXis1aktbo%3D 10.1038/86373 11276208 (Pubitemid 33706348)
9. L Mayer R Shlien 1987 Evidence for function of la molecules on gut epithelial cells in man J Exp Med 166 1471 1483 1:STN:280:DyaL1c%2FmtFSlsw%3D%3D 10.1084/jem.166.5.1471 2960770
10. IN Farstad TS Halstensen B Lien, et al. 1996 Distribution of p7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue Immunology 89 227 237 1:CAS:528:DyaK28Xmt1Kiu7Y%3D 10.1046/j.1365-2567.1996.d01- 727.x 8943719
11. J Holmgren C Czerkinsky 2005 Mucosal immunity and vaccines Nat Med 11 545 553 10.1038/nm1213 (Pubitemid 40562303)
12. S Sakaguchi K Wing M Miyara 2007 Regulatory. T cells-a brief history and perspective Eur J Immunol 37 S116 S123 1:CAS:528:DC%2BD2sXhsVSgur7J 10.1002/eji.200737593 17972355 (Pubitemid 350131275)
13. AM Mowat 2005 Dendritic cells and immune responses to orally administrated antigens Vaccine 23 1797 9 1:CAS:528:DC%2BD2MXhsleju7Y%3D 10.1016/j.vaccine.2004.11.008 15734044 (Pubitemid 40331847)
14. K Mahnke TS Johnson S Ring, et al. 2007 Tolerogenic dendritic cells and regulatory T cells: a two-way relationship J Dermatol Sci 46 3 159 67 1:CAS:528:DC%2BD2sXksV2mur8%3D 10.1016/j.jdermsci.2007.03.002 17428639 (Pubitemid 46601842)
15. EJ Ryan LM Daly KHG Mills 2001 Immunomodulators and delivery systems for vaccination by mucosal routes Trends Biotechnol 19 8 293 304 1:CAS:528:DC%2BD3MXltVaktL8%3D 10.1016/S0167-7799(01)01670-5 11451471 (Pubitemid 32635187)
16. Q Kong L Richter YF Yang, et al. 2001 Oral immunization with hepatitis B surface antigen expressed in transgenic plants Proc Natl Acad Sci U S A 98 20 11539 11544 1:CAS:528:DC%2BD3MXnt12jsrs%3D 10.1073/pnas.191617598 11553782 (Pubitemid 32928764)
17. J Mestecky Z Moldoveanu SM Michalek, et al. 1997 Current opinions for vaccine delivery systems by mucosal routes J Control Release 48 243 257 1:CAS:528:DyaK2sXmtlOmt7c%3D 10.1016/S0168-3659(97)00036-9 (Pubitemid 27401982)
18. A Kostrzak MC Gonzalez D Guetard, et al. 2009 Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells Vaccine 27 35 4798 4807 1:CAS:528:DC%2BD1MXos12qtLg%3D 10.1016/j.vaccine.2009.05.092 19539581
19. R Greco M Michel D Guetard, et al. 2007 Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent vaccine Vaccine 25 8228 40 1:CAS:528:DC%2BD2sXhtlahurrJ 10.1016/j.vaccine.2007.09.061 17976876 (Pubitemid 350087389)
20. SM Alavian SV Tabatabaei 2010 Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: A meta-analysis of controlled clinical trials Clin Therapeut 32 1 1 10 1:CAS:528: DC%2BC3cXosVajsLs%3D 10.1016/j.clinthera.2010.01.005
21. PCY Woo L Wong B Zheng, et al. 2001 Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium Vaccine 9 20-22 2945 2954 10.1016/S0264-410X(00)00530-2 (Pubitemid 32244288)
22. MD Lubeck AR Davis M Chengalvala, et al. 1989 Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus Proc Natl Acad Sci USA 86 6763 6767 1:CAS:528:DyaL1MXlslajuro%3D 10.1073/pnas.86.17.6763 2570422
23. MA Jepson MA Clark N Foster, et al. 1996 Targeting to intestinal M cells J Anat 189 507 516 8982824
24. MA Clark MA Jepson NL Simmons BH Hirst 1995 Expression of junction-associated proteins differentiates mouse intestinal M cells from enterocytes Tissue Res 282 455 461 1:CAS:528:DyaK28XktlKksA%3D%3D 10.1007/BF00318877
25. MR Neutra T Phillips E Mayer, et al. 1987 Intermediate filaments as mechanical integrators of cellular space Cell Tissue Res 247 537 546 1:CAS:528:DyaL2sXhtlGrurY%3D 10.1007/BF00215747 3568100 (Pubitemid 17019581)
26. E Gulberg AV Keita KS Salim, et al. 2006 Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches J Pharmacol Exp Ther 319 632 639 10.1124/jpet.106.107847
27. E Harokopakis G Hajishengallis SM Michalek 1998 Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system Infect Immun 66 9 4299 304 1:CAS:528: DyaK1cXlslCrtrk%3D 9712781
28. J Pappo TH Ermak HJ Steger 1991 Monoclonal antibody directed targeting of fluorescent polystyrene microsphere to Peyer's patches Immunology 73 277 280 1:CAS:528:DyaK3MXltF2qtrY%3D 1879877
29. C Porta PS James AD Phillips, et al. 1992 Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery Exp Physiol 77 929 932 1:STN:280:DyaK3s7ktl2guw%3D%3D 1489550
30. CJ Kirby G Gregoriadis 1984 Preparation of liposomes containing factor VIII for oral treatment of haemophilia J Microencap 1 1 33 45 1:CAS:528:DyaL2cXks1Sjurs%3D 10.3109/02652048409031535
31. Okada J, Cohen S, Langer RS, inventors; Massachusetts Institute of Technology, assignee: Oral delivery of vaccines using polymerized liposomes. US patent 5762904. June 9, 1998.
32. C Chiou LP Tseng MC Deng, et al. 2009 Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens Biomaterials 30 5862 5868 1:CAS:528:DC%2BD1MXpvFCns7c%3D 10.1016/j.biomaterials. 2009.06.046 19608270
33. Y Hassan JM Brewer J Alexander R Jennings 1996 Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems Vaccine 4 1581 1589 10.1016/S0264-410X(96)00155-7 (Pubitemid 27041908)
34. S Jain P Singh V Mishra SP Vyas 2005 Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B Immunol Letters 101 41 49 1:CAS:528:DC%2BD2MXhtVWhtLvI 10.1016/j.imlet.2005.04. 002 (Pubitemid 41297497)
35. R Schubert H Jaroni J Schoelmerich KH Schmidt 1983 Studies on the mechanism of bile salt-induced liposomal membrane damage Digestion 28 181 190 1:CAS:528:DyaL2cXhslalsr4%3D 10.1159/000198984 6365666
36. M Conacher J Alexander JM Brewer 2001 Oral immunization with peptide and protein antigens by formulations in lipid vesicles incorporating bile salts (bilosomes) Vaccine 19 2965 2974 1:CAS:528:DC%2BD3MXit1Wgtb0%3D 10.1016/S0264-410X(00)00537-5 11282208 (Pubitemid 32244290)
37. A Shukla K Khatri PN Gupta, et al. 2008 Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes) J Pharm Pharmaceut Sci 11 1 59 66 1:CAS:528:DC%2BD1MXht1ClsLnI
38. A Shukla OP Katare B Singh SP Vyas 2010 M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes International Journal of Pharmaceutics 385 47 52 1:CAS:528: DC%2BD1MXhs1SlsLzM 10.1016/j.ijpharm.2009.10.027 19835938
39. A Rieux V Fievez M Garinot, et al. 2006 Nanoparticles as potential oral delivery systems of protein and vaccines: a mechanistic approach J. Control Release 116 1 1 27 10.1016/j.jconrel.2006.08.013 17050027 (Pubitemid 44792295)
40. SP Vyas PN Gupta 2007 Implication of nanoparticle/microparticle in mucosal vaccine delivery Expert rev vaccine 6 3 401 418 1:CAS:528: DC%2BD2sXmtVGit7g%3D 10.1586/14760584.6.3.401 This article provides a detailed description of the use of polymeric particles in mucosal vaccine delivery (Pubitemid 46911603)
41. DJ Bharali SA Mousa Y Thanavala 2007 Micro- and nanoparticle-based vaccines for hepatitis B Adv Exp Med Biol 601 415 421 10.1007/978-0-387-72005-0- 44 17713030 The authors discuss the efforts made in the development of PLGA micro- and nanoparticles for HBsAg delivery
42. K Allaoui-Attarki E Fattal S Pecquet, et al. 1998 Mucosal immune genicity elicited in mice by oral vaccination with phos-phorylcholine encapsulated in poly (D, L-lactide-co-glycolide) microspheres Vaccine 7 685 691 10.1016/S0264-410X(97)00261-2 (Pubitemid 28172533)
43. PN Gupta S Mahor A Rawat, et al. 2006 Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation International Journal of Pharmaceutics 318 163 173 1:CAS:528:DC%2BD28XmsVGltr8%3D 10.1016/j.ijpharm.2006.03.017 16621367 (Pubitemid 43963301)
44. Mishra N, Tiwari S, Vaidya B, et al.: Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B, Journal of Drug Targeting 2010:1-12 Early Online.
45. AK Jain AK Goyal N Mishra, et al. 2010 PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B International Journal of Pharmaceutics 387 1-2 253 262 1:CAS:528:DC%2BC3cXhs1Whtro%3D 10.1016/j.ijpharm.2009.12.013 20005936
46. O Borges J Tavares AD Sousa, et al. 2007 Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles European Journal of Pharmaceutical Sciences 32 4-5 278 290 1:CAS:528:DC%2BD2sXht12jt7zP 10.1016/j.ejps.2007.08.005 17884394 (Pubitemid 350051890)
47. R Rajkannan MD Dhanaraju D Gopinath, et al. 2006 Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles Vaccine 24 24 5149 5157 1:CAS:528:DC%2BD28Xltlems74%3D 10.1016/j.vaccine.2006.04.011 16713035 These investigators report that polymeric particle-based vaccine can be designed to obviate the need for repeated administrations (Pubitemid 43818197)